Department of Medicine, College of Medicine, University of Ibadan, Ibadan, Nigeria.
Department of Medicine, University College Hospital, Ibadan, Nigeria.
Afr Health Sci. 2023 Mar;23(1):72-82. doi: 10.4314/ahs.v23i1.9.
Data regarding the features and outcomes of hospitalized COVID-19 patients in Africa are increasingly available.
To describe socio-demographic, clinical and laboratory characteristics and outcomes of COVID-19 patients.
A cross-sectional study of 86 adult patients hospitalized with COVID-19 between March and November 2020. Characteristics were described in survivors and non-survivors.
Mean age was 60.9±16.1 years, 53(61.6%) were male. Co-morbidities were found in 77(89.5%) patients. On severity, 6(7%) were mild, 23(26.7%) moderate, 51(59.3%) severe and 6(7%) critical. Oxygen saturation and respiratory rate were 71±22% and 38±11/minute in non-survivors and 90±7% and 31±7/minute in survivors respectively (p<0.001, p<0.001)). Overall mortality was 47.7% with no death among patients with mild disease and deaths in all patients with critical disease. Duration of hospitalization was 2.0(1.0-4.5) days in those who died and 12(7.0-15.0) days in those who survived (p<0.001). Of the 42 patients that received dexamethasone, 11(26.2%) died, while 31(73.8%) survived (p=<0.001).
Most of the patients had co-morbidities and there was high mortality in patients with severe and critical COVID-19. Mean oxygen saturation was low and respiratory rate high overall. Factors associated with mortality included: Significantly greater hypoxia and tachypnea, less dexamethasone use and shorter hospitalization.
关于非洲住院 COVID-19 患者的特征和结局的数据越来越多。
描述 COVID-19 患者的社会人口学、临床和实验室特征及结局。
对 2020 年 3 月至 11 月期间因 COVID-19 住院的 86 例成年患者进行横断面研究。描述幸存者和非幸存者的特征。
平均年龄为 60.9±16.1 岁,53 例(61.6%)为男性。77 例(89.5%)患者存在合并症。严重程度方面,6 例(7%)为轻症,23 例(26.7%)为中度,51 例(59.3%)为重症,6 例(7%)为危重症。非幸存者的血氧饱和度和呼吸频率分别为 71±22%和 38±11/min,幸存者分别为 90±7%和 31±7/min(p<0.001,p<0.001)。总死亡率为 47.7%,轻症患者无一例死亡,危重症患者全部死亡。死亡患者的住院时间为 2.0(1.0-4.5)天,存活患者为 12(7.0-15.0)天(p<0.001)。接受地塞米松治疗的 42 例患者中,11 例(26.2%)死亡,31 例(73.8%)存活(p<0.001)。
大多数患者存在合并症,重症和危重症 COVID-19 患者死亡率较高。总体而言,血氧饱和度较低,呼吸频率较高。与死亡率相关的因素包括:明显的缺氧和呼吸急促、较少使用地塞米松和较短的住院时间。